Lastly, the majority of respondents to the market investigation considered that the
large portfolio of products of dairy enzymes and dairy cultures would not give the merged entity the ability to exclude rivals and it is not commercial practice to sell together the affected product bundles (lactase-protease, lactase-transglutaminase, coagulants-protease, coagulants-transglutaminase as well as any bundles across other relevant pairs).